Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029255 | 0.78 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1GAAMAPTMEN1 | |
| SCHEMBL716132 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL16327606 | 0.62 | L3MBTL1 (0.47) | ALDH1A1NPC1RAB9AL3MBTL1GAA | |
| SCHEMBL11528288 | 0.62 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1RAB9AL3MBTL1GAA | |
| SCHEMBL21469472 | 0.62 | NPC1 (0.39) | ALDH1A1NPC1RAB9AL3MBTL1MAPT | |
| SCHEMBL2526653 | 0.62 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL12795882 | 0.61 | ADAM17 (0.44) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL6388210 | 0.59 | NPC1 (0.44) | NPC1RAB9AL3MBTL1GAAMEN1 | |
| SCHEMBL20043720 | 0.59 | NPC1 (0.36) | SMN1; SMN2ALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL14031499 | 0.59 | NPC1 (0.36) | NPC1RAB9AL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638938-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECH INC (US) | 2017-04-12 | — | — | EP | claimed |
| US-8124643-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-8039504-B2 | heating a mixture of anti-tricyclo[3.2.2.0]non-6-ene-endo-8, endo-9-dicarboxylic acid anhydride, 4-(trifluoromethyl)benzhydrazide, and ethanol at reflux, concetrating and recrystallizing; 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide | SIGA TECHNOLOGIES, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-7737168-B2 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-06-15 | — | — | US | claimed |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | claimed |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2006-10-19 | — | — | US | claimed |
| US-12464887-B2 | Light-emitting element, lighting device, light-emitting device, and electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| US-20230071734-A1 | Light-Emitting Element, Lighting Device, Light-Emitting Device, And Electronic Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2023-03-09 | — | — | US | disclosed |
| US-11462704-B2 | Light-emitting element, lighting device, light-emitting device, and electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2022-10-04 | — | — | US | disclosed |
| US-20210384455-A1 | Light-Emitting Element, Lighting Device, Light-Emitting Device, and Electronic Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20200251676-A1 | Light-Emitting Element, Lighting Device, Light-Emitting Device, and Electronic Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-10636992-B2 | Light-emitting element, lighting device, light-emitting device, and electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20190058145-A1 | Light-Emitting Element, Lighting Device, Light-Emitting Device, and Electronic Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20090114926-A1 | Light-emitting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090085479-A1 | Light-emitting element, lighting device, light-emitting device, and electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-04-02 | — | — | US | disclosed |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080006822-A1 | Light-emitting element, light-emitting device and an electronic device | SEMICONDUCTOR ENERGY LABORATORY CO. , LTD. | 2008-01-10 | — | — | US | disclosed |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | SMN1; SMN2 3328/4885ALDH1A1 1119/4885NPC1 1937/4885 |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | SMN1; SMN2 2395/4885ALDH1A1 1899/4885NPC1 1517/4885 |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | SMN1; SMN2 2395/4885ALDH1A1 1899/4885NPC1 1517/4885 |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | SMN1; SMN2 3328/4885ALDH1A1 1119/4885NPC1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.